Proton pump inhibitors (PPIs) are very effective and suitable for certain indications and treatment periods, but there is an increasing trend towards “off-label” prescriptions. To ensure that temporary administration for a specific indication does not become an unreflected permanent medication, North American experts have summarized ten best practice recommendations to help decide whether discontinuation (“deprescribing”) of PPIs could be an option to consider.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- GASTROENTEROLOGIE PRAXIS
Related Topics
You May Also Like
- Gastric carcinoma
Ways of precision oncology
- Endometrial Cancer
Immunological drivers and new therapeutic pathways
- Exercise for type 1 diabetes
Cyclists and runners with an increased risk of hypoglycemia
- Ozanimod for relapsing-remitting multiple sclerosis
Signs of improved tolerability with prolonged treatment
- When basal cell carcinomas prove difficult to treat
Reaching the goal with innovative therapy strategies
- Irritable Bowel Syndrome
IBS or endometriosis?
- Type 2 diabetes: sarcopenia and frailty
How can the breakdown of skeletal muscles be stopped?
- Cholangiocarcinoma